Cost of Severe Chronic Obstructive Pulmonary Disease Exacerbations in a High Burden Region in North India
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease; 2013.
http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf . Accessed April 27, 2014. - Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397–412. DOI: 10.1183/09031936.06.00025805
- Mathers CD and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):
e442 . DOI: 10.1371/journal.pmed.0030442 - Wedzicha JA and Seemungal TA. COPD exacerbations: Defining their cause and prevention. Lancet. 2007 Sep. 1; 370(9589): 786–96.
- Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60(11): 925–31. DOI: 10.1136/thx.2005.040527
- Bakerly ND, Davies C, Dyer M and Dhillon P. Cost analysis of an integrated care model in the management of acute exacerbations of chronic obstructive pulmonary disease. Chron Respir Dis. 2009; 6(4): 201–8. DOI: 10.1177/1479972309104279
- Garcia-Aymerich J, Pons IS, Mannino DM, Maas AK, Miller DP and Davis KJ. Lung function impairment COPD hospitalisations and subsequent mortality. Thorax. 2011; 66(7): 585–90. DOI: 10.1136/thx.2010.152876
- Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12): 1128–38. DOI: 10.1056/NEJMoa0909883
- Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM and Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003; 58(2): 100–5. DOI: 10.1136/thorax.58.2.100
- Pasquale MK, Sun SX, Song F, Hartnett HJ and Stemkowski SA. Impact of exacerbations on health care costs and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7: 757–764. DOI: 10.2147/COPD.S36997
- WHO. Global Infobase.
https://apps.who.int/infobase/Index.aspx . Accessed March 10, 2012. - Jindal SK, Aggarwal AN, Gupta D, Agarwal R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults. Int J Tuberc Lung Dis. 2012; 16(9): 1270–7. DOI: 10.5588/ijtld.12.0005
- Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM, et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Res Med. 2008; 102(3): 413–21. DOI: 10.1016/j.rmed.2007.10.010
- Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C, et al. The cost of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002; 96(9): 700–8. DOI: 10.1053/rmed.2002.1334
- Miravitlies M, Murio C, Guerrero T, Gisbert R and DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbation of chronic bronchitis COPD. Chest. 2002; 121(5): 1449–55. DOI: 10.1378/chest.121.5.1449
- Veettil SK, Ma S, Rajiah K and Kumar S. Cost of acute exacerbation of COPD in patients attending government hospital in Kerala, India. Int J of Pharmacy and Pharmaceutical Sciences. 2012; 4(3): 659–61.
- WHO. WHO-CHOICE Unit Cost Estimates 2007–2008.
http://www.who.int/choice/country/country_specific/en/index.html . Accessed April 27, 2014. - Government of India Labour Bureau.
http://labourbureau.nic.in/indnum.html . - Molinari NM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine. 2007 Jun. 28; 25(27): 5086–96.
- Press Trust of India.
India’s per capita income rises to Rs 5,729 per month . Business Standard. February 7, 2013.http://www.business-standard.com/article/economy-policy/india-s-per-capita-income-rises-to-rs-5-729-per-month-113020700995_1.html . - US Dollar (USD) to Indian Rupee (INR) exchange rates.
http://www.exchangerates.org.uk/USD-INR-exchange-rate-history.html . - Press Trust of India.
India’s per capita income rises to Rs 5,729 per month . Business Standard. February 7, 2013.http://www.business-standard.com/article/economy-policy/india-s-per-capita-income-rises-to-rs-5-729-per-month-113020700995_1.html . - Murthy KJR and Sastry JG. Economic burden of chronic obstructive lung disease, National commission on macroeconomics and health burden of disease in India. 2005; 264–271.
- Hilleman DE, Dewan N, Malesker M and Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000; 118(5): 1278–85. DOI: 10.1378/chest.118.5.1278
- Sullivan SD, Ramsey SD and Lee TA. The economic burden of COPD. Chest. 2000; 117(2 Suppl.): 5S–9S. DOI: 10.1378/chest.117.2_suppl.5S
- Dalal AA, Liu F and Riedel AA. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis. 2011; 6: 533–42. DOI: 10.2147/COPD.S24591
- Dahl R and Lofdahl CG. The economic impact of COPD in North America and Europe. Analysis of the Confronting COPD survey. Introduction. Respir Med. 2003; 97(Suppl C): S1–2.
- Motegi T, Yamada K and Kida K. Cost analysis for inpatient therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. Nihon Kokyuki Gakkai Zasshi. 2006; 44(11): 787–94.
- Toy EL, Gallagher KF, Stanley EL, Swensen AR and Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: A review. COPD. 2010; 7(3): 214–28. DOI: 10.3109/15412555.2010.481697
- Donaldson GC, Seemungal TAR, Bhowmik A and Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57(10): 847–852. DOI: 10.1136/thorax.57.10.847
- Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 1998; 351: 773–780. DOI: 10.1016/S0140-6736(97)03471-5
- Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274: 1852–7. DOI: 10.1001/jama.1995.03530230038027
- Connors AF,
Jr. , Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154: 959–967. DOI: 10.1164/ajrccm.154.4.8887592 - Shibuya K, Mathers CD and Lopez AD.
Chronic Obstructive Pulmonary Disease (COPD): Consistent estimates of incidence, prevalence and mortality by WHO region. Global Programme on Evidence for Health Policy , World Health Organization; 2001. - Langsetmo L, Platt RW, Ernst P and Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008; 177(4): 396–401. DOI: 10.1164/rccm.200708-1290OC
- Bhome AB. COPD in India: Iceberg or volcano. J Thorac Dis. 2012; 4(3): 298–309.
DOI: https://doi.org/10.5334/aogh.2423 | Journal eISSN: 2214-9996
Language: English
Published on: Jan 22, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2019 Parvaiz A. Koul, Aqsa Amin Nowshehr, Umar H. Khan, Rafi A. Jan, S. U. Shah, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.